Articles On Starpharma Holdings (ASX:SPL)

Australian Biotech Starpharma (SPL) has released its quarterly cash flow report for the December 2019 quarter Cash balance for the end of the quarter was just under $36 million The company also had net operating cash outflows of $500,000...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

In afternoon trade the S&P/ASX 200 index is on course to start the week on a disappointing note. At the time of writing the benchmark index is down 0.45% to 6,790.8 points. Four shares that have not let that hold them back today are li...

AstraZeneca has begun the phase 1 clinical trial for a cancer treatment drug Roughly $4.29 million will be paid to StarPharma (SPL) as a result of the trial The drug comes under a multi-product license for AstraZeneca to develop treatments...

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Monday. In morning trade the dendrimer products developer’s shares are up 2% to $1.22 following an announcement. What did Starpharma announce? This morning Starpha...

Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the next big thing. The more complex the sector, the more we are likely to rely on informat...

Starpharma Holdings Limited (ASX: SPL) has received a $4.9 million R&D tax incentive refund related to the cost of research and development during FY19. As per the company, the refund will strengthen the company’s cash position. For the...

Pharmaxis (ASX:PXS) has some big news from its German partner, but won’t yet say whether it’s good or bad. The company has been waiting on pharmaceutical major Boehringer Ingelheim to decide whether it wants to go ahead and further develop...

The primary research tool in advancing medical knowledge and patient care are clinical trials conducted when doctors do not know whether a new approach works well for patients and is safe, and which treatments or strategies work best for ce...

Starpharma Holdings Limited (ASX: SPL) has announced the completion of the phase 1 component of its phase 1 / 2 trial for DEP® cabazitaxel.  The trial was able to meet its objective of assessing safety, tolerability and preliminary efficacy...

In afternoon trade the S&P/ASX 200 index is on course to follow the lead of U.S. markets and drop lower. At the time of writing the benchmark index is down 0.2% to 6,716.5 points. Four shares that have not let that hold them back are l...

10 Dec 2019 - Starpharma's (ASX:SPL) prostate cancer drug DEP cabazitaxel has successfully completed its phase one trials.

Starpharma’s (ASX:SPL) cancer drug has passed its first test, proving to be safe and delivering a recommended dose. The company is taking a version of cancer drug Jevtana through phase 1 and 2 clinical trials, as a treatment for cancers inc...

Shares in Starpharma (ASX: SPL) couldn't get up by market close today despite a landmark approval for the biotech's VivaGel condoms to be marketed in Europe. The Melbourne-based company describes the condom as a world-first product and th...

Starpharma (ASX:SPL) has announced it has been granted marketing approval for its VivaGel condom in Europe. 

21 Nov 2019 - Starpharma (ASX:SPL) has been granted marketing approval for the VivaGel® condom in Europe.

The Starpharma Holdings Limited (ASX: SPL) share price will be on watch on Thursday following an after-market announcement. What did Starpharma announce? This afternoon Starpharma announced that it has been granted marketing approval for...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Wednesday. In morning trade the dendrimer products developer’s shares are up 3% to $1.36. Why is the Starpharma share price pushing higher? Investors have been buy...

Health care sector in Australia is growing tremendously and players are investing a considerable amount in their research and development for providing new treatment for rare diseases and finding therapies for unmet medical needs. Clinical...

The Starpharma Ltd (ASX: SPL) share price has been fluctuating in trade today after its latest development update. Starpharma shares climbed as high as $1.19 on the announcement, but have since dipped back down to $1.15 at the time of writ...

31 Oct 2019 - Starpharma (ASX:SPL) says their next internal development candidate, DEP® gemcitabine significantly enhanced anti-tumour activity compared with Gemzar® both alone and…

The Starpharma Holdings Limited (ASX: SPL) share price was a strong performer on Wednesday. The dendrimer products developer’s shares finished the day 5% higher at $1.16. Why did the Starpharma share price race higher today? The catalyst f...

Pharmacy businesses are increasingly becoming a focal point for investments by businesses and market players, given the huge market opportunity that lies ahead. As per the US National Institute of Health, the development of a new medicine i...

The S&P/ASX 200 index is on course to finish the week on a positive note. In afternoon trade the benchmark index is up almost 0.5% to 6,708.8 points. Four shares that have failed to follow the market higher today are listed below. Here...

It certainly has been a positive day of trade for the Stavely Minerals Ltd (ASX: SVY) share price. In afternoon trade the copper and gold-focused mineral exploration company’s shares are up an incredible 287% to 93 cents. Why is the Stavel...

In afternoon trade the S&P/ASX 200 index is on course to record another decline. At the time of writing the benchmark index is down 0.35% to 6,687.3 points. Four shares that have not let that hold them back are listed below. Here’s why...

The Starpharma Holdings Limited (ASX: SPL) share price has been a strong performer on the All Ords on Thursday. In morning trade the dendrimer products developer’s shares are up 9% to $1.20. Why is the Starpharma share price charging highe...

Shares in Bionomics (ASX:BNO) have flown to their highest point since May as it looks redo the failed post traumatic stress disorder trial that wiped out 66 per cent of the company’s value last October. Bionomics conducted a pharmacokinetic...

The Starpharma Holdings Limited (ASX: SPL) share price has pushed higher on Thursday following the release of an update on its DEP irinotecan formulation. At the time of writing the dendrimer products developer’s shares are up 1% to $1.13....

Yesterday, Trevor Hoey looked at the turnaround in the health services sector. He pointed out that the S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start o...

In light of the volatility that has rocked global equities markets including the ASX, Finfeed felt it was timely to assess the damage on a sector by sector basis. What’s more, we have come up with six stocks that appear to have plenty going...

One of the best in the world, Australian health care sector is unceasingly advancing technologies to deliver the best health care services. Despite, a few uncertainties, health care sector caught investors’ attention to invest in leading bi...

03 Sep 2019 - Starpharma (ASX:SPL) has today announced that it has received a further regulatory approval in another Asian country for its product VivaGel® BV.

29 Aug 2019 - Starpharma (ASX:SPL) has seen positive results with targeted DEO using antibody fragment in human ovarian cancer model.

The Avita Medical Ltd (ASX: AVH) share price has risen more than 500% since January. This may lead to some investors avoiding Avita Medical shares in fear of paying too much. However, even after this massive price rise, I believe the share...

The Starpharma Holdings Limited (ASX: SPL) share price has been amongst the best performers on the All Ordinaries index on Wednesday. In morning trade the dendrimer products developer’s shares raced as much as 6% higher to $1.21 following...

On Stockhead today, the disconnect between federal and state governments on coal, private equity deals are rising and an ‘avalanche’ is laying waste to lithium prices. But first, here’s what you need to know.   The day ahead Data Today the...

The Australian health system is tagged amongst the best in the world and focusses on providing safe and affordable health care for all the Australians. The federal, state and local government jointly run the system to ensure its adherence....

August 2019 is proving to be much more than just a reporting season. Along with the earning releases and outlook notifications, the companies have been hinting towards the various feathers in their caps. Amid these announcements came an upd...

The PolyNovo Ltd (ASX: PNV) share price was amongst the best performers on the All Ordinaries index on Thursday. The medical device company’s shares were up over 10% at one stage before ending the day 9% higher at $1.60. Why did the PolyNo...

Shares in Immuron took a 17 per cent hit this morning after the company revealed its IMM-124E drug did not work in a trial with patients suffering from severe alcoholic hepatitis. Immuron (ASX:IMM), which is developing oral drugs for gut di...

The Starpharma Ltd  (ASX: SPL) share price has jumped 8% higher in early trade after the company provided an update on its phase 1/2 clinical trial for its colorectal cancer drug, DEP irinotecan. What did Starpharma say in its latest updat...

The Starpharma Holdings Limited (ASX: SPL) share price rose 3% after giving its June 2019 trading update. Starpharma describes itself as a world leader in the development of dendrimer enhanced products (DEP) for pharmaceutical, life science...

This morning healthcare business Starpharma Ltd (ASX: SPL) reported a net investing and operating cash outflow for the quarter ending June 30 2019 on revenue of $626,000. For the full financial year it reported an investing and operating c...

I have recently spent some time reviewing the annual reports and announcements from S&P/ASX 200 (INDEXASX: XJO) index-listed company, Starpharma Holdings Limited (ASX: SPL) to assess the merit of buying SPL shares. Starpharma shares la...

The Starpharma Holdings Limited (ASX: SPL) share price has been a positive performer again on Thursday. In afternoon trade the dendrimer products developer’s shares have stormed almost 5% higher to $1.44. Why is the Starpharma share price...

The S&P/ASX 200 index is fighting hard to keep its head above water on Thursday. In afternoon trade the benchmark index is up slightly to 6,643.5 points. Four shares that have climbed more than most today are listed below. Here’s why t...

Super Retail Group Limited, Domain Holdings Australia Limited, Metcash Limited and Starpharma Holdings Limited have depicted a similar upward trend in generating a good YTD return. Let us have a view on the recent updates of these players l...

Australian company Starpharma (ASX:SPL) has announced a new development and option agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product version of one of the UK company's oncology medicines.